Skip to main content

Table 1 Associations between ZNF331 methylation and clinical and molecular features

From: Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer

  Total ZNF331 unmethylated ZNF331 methylated P value
n n (%) n (%)
No. of patients 423 122 (29) 301 (71)  
Gender     0.165
 Male 213 68 (32) 145 (68)  
 Female 210 54 (26) 156 (74)  
Age     0.074
 < 60 70 26 (37) 44 (63)  
 60–74 178 55 (31) 123 (69)  
 ≥ 75 175 41 (23) 134 (77)  
Stage     0.683
 I 79 20 (25) 59 (75)  
 II 169 51 (30) 118 (70)  
 III 118 32 (27) 86 (73)  
 IV 56 19 (34) 37 (66)  
Localization     < 0.001
 Right colon 167 27 (16) 140 (84)  
 Left colon 130 47 (36) 83 (64)  
 Rectum 121 46 (38) 75 (62)  
MSI status     < 0.001
 MSS 325 111 (34) 214 (66)  
 MSI 89 8 (9) 81 (91)  
BRAF     < 0.001
BRAF wt 356 120 (34) 236 (66)  
BRAF mut 67 2 (3) 65 (97)  
CIMP     < 0.001
CIMP− 355 121 (34%) 234 (66)  
CIMP+ 65 0 (0) 65 (100)  
MLH1 methylation     < 0.001
MLH1 unmeth 360 117 (32.5) 243 (67.5)  
MLH1 meth 60 4 (7) 56 (93)  
Series     0.439
 Oslo 3 59 14 (24) 45 (76)  
 Oslo 2 364 108 (30) 256 (70)  
  1. Meth methylated, mut mutation, No. number, unmeth unmethylated, wt wild type